Glucagon-Like Peptide (GLP) - 1 Receptor Agonists New Insights and New Strategies for Successful Long Term Diabetes Management
WebcastFaculty
OVERVIEW
Glucagon-Like Peptide (GLP) - 1 Receptor Agonists New Insights and New Strategies for Successful Long Term Diabetes Management is organized by National Association for Continuing Education (NACE) and will be held during Jun 27, 2017 - Jun 26, 2018.
The target audience for this medical event is Primary Care Providers. This CME Conference has been approved for a maximum of 1.0 AMA PRA Category 1 Credits.
Conference Description:
Due to the progressive nature of T2DM, oral drugs alone are often insufficient for glycemic control, and most patients eventually need insulin therapy to reach/maintain glycemic targets. However, several clinician and patient barriers, including fears of hypoglycemia and weight gain, limit the use of insulin in practice.
The glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may be alternatives to insulin in certain patients. The efficacy and benefits of these agents have been clearly demonstrated in clinical studies, but in practice, clinicians may have gaps in perception and knowledge of these and other T2DM therapies. This webcast, from the NACE Emerging Challenges in Primary Care 2017 conference, addresses these issues and provides strategies on how to incorporate GLP-1 RAs into practice. This webcast was recorded live and is being used with the permission of the presenters.
Conference Objectives are:
• Discuss the role of postprandial hyperglycemia in the pathogenesis of diabetic complications.
• Incorporate GLP-1 RA therapy into practice to reduce post-prandial hyperglycemia and decrease glycemic variability.
• Compare GLP-1 RAs for glycemic efficacy and differential impact on postprandial glycemic control.
• Discuss various GLP-1 RA combination strategies with, or as a possible alternative to, basal insulin in the diabetic patient not at glycemic target.
Additional details will be posted as soon as they are available.
The target audience for this medical event is Primary Care Providers. This CME Conference has been approved for a maximum of 1.0 AMA PRA Category 1 Credits.
Conference Description:
Due to the progressive nature of T2DM, oral drugs alone are often insufficient for glycemic control, and most patients eventually need insulin therapy to reach/maintain glycemic targets. However, several clinician and patient barriers, including fears of hypoglycemia and weight gain, limit the use of insulin in practice.
The glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may be alternatives to insulin in certain patients. The efficacy and benefits of these agents have been clearly demonstrated in clinical studies, but in practice, clinicians may have gaps in perception and knowledge of these and other T2DM therapies. This webcast, from the NACE Emerging Challenges in Primary Care 2017 conference, addresses these issues and provides strategies on how to incorporate GLP-1 RAs into practice. This webcast was recorded live and is being used with the permission of the presenters.
Conference Objectives are:
• Discuss the role of postprandial hyperglycemia in the pathogenesis of diabetic complications.
• Incorporate GLP-1 RA therapy into practice to reduce post-prandial hyperglycemia and decrease glycemic variability.
• Compare GLP-1 RAs for glycemic efficacy and differential impact on postprandial glycemic control.
• Discuss various GLP-1 RA combination strategies with, or as a possible alternative to, basal insulin in the diabetic patient not at glycemic target.
Additional details will be posted as soon as they are available.
FACULTY
SPECIALITIES
Endocrinology, Metabolism and Diabetes
Quick Links